益佰制药被罚暂时停产、销售小儿止咳糖浆

Core Viewpoint - Guizhou Yibai Pharmaceutical Co., Ltd. has received a suspension notice from the Guizhou Provincial Drug Administration regarding the production and sale of its children's cough syrup due to regulatory non-compliance identified during an inspection by the National Medical Products Administration [1][2]. Summary by Sections Regulatory Action - The company was issued a suspension notice (No. 4 of 2025) due to deficiencies found during an inspection, including incomplete record-keeping and unreliable electronic data recording [1]. - The suspension is in accordance with the relevant regulations and is effective immediately upon receipt of the notice [1]. Financial Impact - The revenue from the children's cough syrup for the years 2021, 2022, 2023, and 2024 was reported as 3.42 million, 4.32 million, 8.38 million, and 1.51 million respectively, representing a small percentage of the company's total revenue at 0.10%, 0.16%, 0.30%, and 0.07% [2]. - The suspension of the children's cough syrup production and sales is not expected to have a significant impact on the company's overall performance [2].